» Articles » PMID: 20696315

What Causes the Death of Dopaminergic Neurons in Parkinson's Disease?

Overview
Journal Prog Brain Res
Publisher Elsevier
Specialty Neurology
Date 2010 Aug 11
PMID 20696315
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

The factors governing neuronal loss in Parkinson's disease (PD) are the subject of continuing speculation and experimental study. In recent years, factors that act on most or all cell types (pan-cellular factors), particularly genetic mutations and environmental toxins, have dominated public discussions of disease aetiology. Although there is compelling evidence supporting an association between disease risk and these factors, the pattern of neuronal pathology and cell loss is difficult to explain without cell-specific factors. This chapter focuses on recent studies showing that the neurons at greatest risk in PD--substantia nigra pars compacta (SNc) dopamine (DA) neurons--have a distinctive physiological phenotype that could contribute to their vulnerability. The opening of L-type calcium channels during autonomous pacemaking results in sustained calcium entry into the cytoplasm of SNc DA neurons, resulting in elevated mitochondrial oxidant stress and susceptibility to toxins used to create animal models of PD. This cell-specific stress could increase the negative consequences of pan-cellular factors that broadly challenge either mitochondrial or proteostatic competence. The availability of well-tolerated, orally deliverable antagonists for L-type calcium channels points to a novel neuroprotective strategy that could complement current attempts to boost mitochondrial function in the early stages of the disease.

Citing Articles

A pilot randomized clinical trial examining the effects of Qigong on inflammatory status and sleep quality in people with Parkinson's disease.

Moon S, Sarmento C, Smirnova I, Colgrove Y, Lai S, Lyons K J Bodyw Mov Ther. 2024; 40:1002-1007.

PMID: 39593404 PMC: 11602653. DOI: 10.1016/j.jbmt.2024.07.025.


Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis.

Hussain M, Moglad E, Afzal M, Sharma S, Gupta G, Sivaprasad G CNS Neurosci Ther. 2024; 30(5):e14763.

PMID: 38790149 PMC: 11126788. DOI: 10.1111/cns.14763.


Effect of Electric Field on α-Synuclein Fibrils: Revealed by Molecular Dynamics Simulations.

Razzokov J, Fazliev S, Makhkamov M, Marimuthu P, Baev A, Kurganov E Int J Mol Sci. 2023; 24(7).

PMID: 37047286 PMC: 10094641. DOI: 10.3390/ijms24076312.


Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson's Disease.

Ahuja M, Kaidery N, Dutta D, Attucks O, Kazakov E, Gazaryan I Antioxidants (Basel). 2022; 11(9).

PMID: 36139853 PMC: 9495572. DOI: 10.3390/antiox11091780.


Synaptic Secretion and Beyond: Targeting Synapse and Neurotransmitters to Treat Neurodegenerative Diseases.

Wei Z, Wei M, Yang X, Xu Y, Gao S, Ren K Oxid Med Cell Longev. 2022; 2022:9176923.

PMID: 35923862 PMC: 9343216. DOI: 10.1155/2022/9176923.